Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Recombinant Mycobacterium Tuberculosis Vaccine (AEC/BC02) in Healthy and Latent TB Subjects
NCT03026972Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- Apr 2018
- Primary completion
- Sep 2018
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of AEC/BC02 in Tuberculosis (TB) (4 arms), sponsored by Zhifei Biological. Primary endpoint: Number of participants with Adverse Events. Started Apr 2018; status: completed.
02
Drugs
AEC/BC02
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03026972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026972.